PEPhillip Adrian Evans

Phillip Adrian Evans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Phillip Adrian Evans has a total of 295 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of physical activity and intensity on clot mechanical microstructure and contraction in middle-aged/older habitual runners

    by J. C. Zaldua, O. Watson, D. J. Gregoire, S. Pillai, Y. Hellsten, K. Hawkins, P. A. Evans

    Background: Exercise in healthy individuals is associated with a hypercoagulable phase, leading to a temporary increase in clot mass and strength, which are controlled by an effective fibrinolytic system. Conversely, people with cardiovascular diseases often have a reduced fibrinolytic pathway, increased clot mass and abnormal clot contraction, resulting in poorer outcomes. We assessed clot microstructure, particularly the contractile forces of clot formation, in response to two exercise intensities in middle-aged/older runners. Methods: Twenty-eight habitual male and female runners aged over 40 years completed a 10 km moderate-intensity run; 14 of them performed a 3 km high-intensity run. Blood samples were collected at baseline, immediately postexercise and after 1 h of rest. Clot structural biomarkers d f, gel time, and measurements of mature clot mechanical properties (gel time, G’ Max and CF max ) were analysed alongside conventional plasma markers. Results: Both exercise intensities altered markers of coagulant activity (PT, APTT and FVIII) and fibrinolysis (D-dimer), indicating hypercoagulability. Compared with longer-duration lower-intensity exercise, d f was greater after short-duration intensified exercise bouts. Following an hour of rest, d f dropped to baseline levels. Additionally, CF max decreased across timepoints at both exercise intensities. This effect was noted after one hour of rest compared with baseline, suggesting continuous fibrinolytic activity postexercise. Conclusion: Exercise transiently induces an intensity-dependent hypercoagulable state, resulting in denser clot formation and a reduced clot contractile force due to fibrinolysis. These findings can help guide the safe commencement of rehabilitation exercise programs for cerebrovascular patients.


  • Open Access

    Ischemic Preconditioning Negatively Affects Thrombogenic Clotting Profile in Cerebral Small Vessel Occlusion Stroke Patients

    by Line Boel Norregaard, Nicolai Rytter, Laura Cathrine Christoffersen, Lasse Gliemann, Christian Stevns Hansen, Matthew Lawrence, Philip Adrian Evans, Christina Kruuse, Ylva Hellsten

    Background: The study evaluated the effect of an acute and a 2-week daily repetitive ischemic preconditioning (IPC) on conduit artery vascular function and thrombogenic clotting profile, in patients with a recent ischemic stroke. Methods: Fourteen patients, aged 71 ± 8 years, with a cerebral small vessel occlusion stroke were included in a randomized, controlled, open-label cross-over study. Treatment consisted of 2 weeks of daily IPC, four 5-min rounds of upper-arm occlusion, interspersed by 5 min rest periods. Control was without treatment. Brachial artery flow-mediated dilation (FMD) was determined at baseline and after the control and treatment periods. Before and after each period, the patients underwent an acute bout of IPC. Blood samples were obtained for thrombogenic clotting profile at baseline and after the acute IPC bout, both before and after the control and treatment periods. Results: The period of daily IPC increased brachial artery diameter but did not influence FMD. Acutely, IPC was found to induce an increase in fractal dimension, indicating a denser clot microstructure, and a reduction in plasma levels of plasminogen activator inhibitor 1 (PAI-1). There was no effect of daily IPC on the basal thrombogenic clotting profile, or on the change in clotting profile induced by acute IPC. Conclusions: Collectively, the data show that acute IPC leads to a prothrombotic clotting profile, despite antiplatelet therapy. Moreover, 2 weeks of daily treatment with IPC does not influence conduit artery vascular function or thrombogenicity in stroke patients.


  • The efficacy of low molecular weight heparin is reduced in COVID-19

    by Oliver Watson, Jun-Cezar Zaldua, Suresh Pillai, Janet Whitley, Matthew Howard, Matthew Lawrence, Karl Hawkins, Keith Morris, Phillip Adrian Evans

    BACKGROUND: A significant degree of mortality and morbidity in COVID-19 is through thromboembolic complications, only partially mitigated by anticoagulant therapy. Reliable markers of infection severity are not fully established. OBJECTIVES: This study investigated whether visco-elastic biomarkers predict disease severity on presentation to the Emergency Department (ED) and how they measure response to anticoagulation METHODS: Patients testing positive for COVID-19 at a large University Teaching Hospital ED were recruited at presentation. Multiple blood samples were taken throughout hospital admission to monitor disease progression with end outcome recorded. Visco-elastic markers, fractal dimension (df) and Time to Gel Point (TGP) which measure the properties of the incipient clot were compared in patients with and without anticoagulation by Low Molecular Weight Heparin (LMWH). RESULTS: TGP and df did not predict severity of infection with COVID-19. Although LMWH prolonged TGP, there was no change in df indicating LMWH did not change clot microstructure. CONCLUSIONS: Therapeutic efficacy of LMWH appears blunted in COVID-19 infection. This may be due to the inflammatory state creating a resistance to LMWH activity, which may explain why LMWH appears less effective in COVID-19 compared to other disease states. COVID-19 was not predicted by visco-elastic testing at the time of ED presentation.


  • Exercise training induces thrombogenic benefits in recent but not late postmenopausal females

    by Line Boel Nørregaard, Kate Aiko Wickham, Thomas Ehlers, Marcos Paulo Rocha, Mads Fischer, Martina H. Lundberg Slingsby, Stephen S. Cheung, Phillip Adrian Evans, Jens Bangsbo, Ylva Hellsten

    Eight weeks of high-intensity exercise training reduces platelet reactivity as well as blood clot density and strength in females ≤5 yr past menopause but not in females ≥10 yr past menopause. The divergent response in the late postmenopausal females may be explained by training-induced low-grade systemic inflammation. These findings suggest that regular physical activity initiated soon after menopause, compared with many years after menopause, may be more efficient for reducing the risk of blood clots.


  • Open Access

    The Impact of Patient Characteristics and Antiplatelet Regimes on Clot Microstructure in Patients Treated for ST Elevation Myocardial Infarction: Clot Microstructure can Evaluate Therapeutic Efficacy

    by Matthew J. Lawrence, Daniel R. Obaid, Ahmed Sabra, Janet Whitley, Rhianwen Quarry, Suresh Pillai, Alexander J. Chase, David Smith, Phylip R. Williams, Karl Hawkins, et al.

    Background: Unfavourable clot microstructure is associated with adverse outcomes in ST elevation myocardial infarction (STEMI). We investigated the effect of comorbidities and anti-platelet treatment on clot microstructure in STEMI patients using fractal dimension (df), a novel biomarker of clot microstructure derived from the visco-elastic properties of whole blood. Methods: Patients with STEMI (n = 187) were recruited sequentially receiving aspirin with Clopidogrel (n = 157) then Ticagrelor (n = 30). Patient characteristics and blood for rheological analysis obtained. We quantified df using sequential frequency sweep tests to obtain the phase angle of the Gel Point which is synonymous with the clot microstructure. Results: Higher df was observed in males (1.755 ± 0.068) versus females (1.719 ± 0.061, p = .001), in patients with diabetes (1.786 ± 0.067 vs 1.743 ± 0.046, p < .001), hypertension (1.760 ± 0.065 vs 1.738 ± 0.069, p = .03) and previous MI (1.787 ± 0.073 vs 1.744 ± 0.066, p = .011) compared to without. Patients receiving Ticagrelor had lower df than those receiving Clopidogrel (1.708 ± 0.060 vs 1.755 ± 0.067, p < .001). Significant correlation with df was found with haematocrit (r = 0.331, p < .0001), low-density lipoprotein (LDL) (r = 0.155, p = .046) and fibrinogen (r = 0.182, p = .014). Following multiple regression analysis, diabetes, LDL, fibrinogen and haematocrit remained associated with higher df while treatment with Ticagrelor remained associated with lower df. Conclusions: The biomarker df uniquely evaluates the effect of interactions between treatment and underlying disease on clot microstructure. STEMI patients with diabetes and elevated LDL had higher df, indicating denser clot. Ticagrelor resulted in a lower df than Clopidogrel signifying a less compact clot.


  • Impaired fibrinolysis in severe Covid-19 infection is detectable in early stages of the disease

    by Oliver Watson, Suresh Pillai, Matthew Howard, Jun-Cezar Zaldua, Janet Whitley, Brian Burgess, Matthew Lawrence, Karl Hawkins, Keith Morris, Phillip Adrian Evans

    BACKGROUND: A significant degree of mortality and morbidity in Covid-19 is due to thromboembolic disease. Coagulopathy has been well described in critically unwell patients on ICU. There is less clear evidence regarding these changes at the time of presentation to the Emergency Department and the progression of disease over time. OBJECTIVE: We sought to investigate whether coagulation markers can predict severity and how they change over the disease course. METHODS: Patients presenting to a single University Teaching Hospital were recruited and followed up if PCR was positive. Alongside routine blood testing, Rotational Thromboelastometry (ROTEM) was performed. Outcome data was recorded for all patients, and ROTEM values were compared across outcome groups. RESULTS: Extem and Intem Maximum Lysis were significantly reduced in those who died or required an ICU admission, indicating a reduced ability to break down clot mass in the most critically unwell patients. CONCLUSION: Comparisons between groups demonstrated that one distinguishing feature between those who require ICU admission or die of Covid-19 compared with those who survive a hospital stay to discharge was the extent to which fibrinolysis could occur. Mortality and morbidity in Covid-19 infection appears in part driven by an inability to break down clot mass.


  • Open Access

    The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker

    by Matthew J. Lawrence, Vanessa Evans, Janet Whitley, Suresh Pillai, Phylip R. Williams, James Coulson, Manju Krishnan, Peter Slade, Kieron Power, Roger H.K. Morris, et al.

    Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28 AF without stroke (AF). Pre‐ and post‐anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df, the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF‐S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood’s ability to form stable clots (no change in df). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics.


  • Open Access

    A comparative study into the effects of venous and arterial blood on clot microstructure in critically unwell patients. Assessment of the diagnostic potential of a biomarker of haemostasis

    by Suresh Pillai, Vanessa Evans, Gareth Davies, Matthew J Lawrence, Janet Whitley, Ceri E Battle, Phylip R Williams, Keith Morris, Phillip A Evans

    Blood for coagulation analysis can be sampled from the arterial or venous system in intensive care units (ICU). The determination of clot microstructure and strength by fractal analysis (d f) gives valuable information in a range of vascular haemostatic disease and sepsis. We aimed to determine if d f could be measured equally and comparatively in arterial or venous blood, and 45 critically ill patients in an ICU were recruited. d f was found to be readily measured in arterial blood with results comparable to those in venous blood and that add value of d f as a potential marker of haemostasis in these patients.


  • The effect of the acute inflammatory response of burns and its treatment on clot characteristics and quality: A prospective case controlled study

    by N.J. Marsden, M. Lawrence, N. Davies, G. Davies, K. Morris, P.R. Williams, I.S. Whitaker, P.A. Evans


  • In vitro clot model to evaluate fibrin-thrombin effects on fractal dimension of incipient blood clot

    by Ahmed Sabra, Matthew J. Lawrence, Dan Curtis, Karl Hawkins, Phylip R. Williams, Phillip A. Evans

    INTRODUCTION: This aim of this study is to investigate the individual effects of varying concentrations of thrombin and fibrinogen on clot microstructure (characterised through the fractal dimension of the incipient clot network, df) and clot formation time ( TGP) using a fibrin-thrombin clot model. df and TGP markers are measured using a haemorheological method that has already been investigated for whole blood. METHODS: This is an in vitro study using three thrombin concentrations (0.1, 0.05 and 0.02 NIH/ml) and two fibrinogen concentrations (8 mg/ml and 12 mg/ml) to investigate a fibrin-thrombin clot model. The haemorheological changes were measured at the gel point using df and TGP. RESULTS: Fractal dimension (df) increased with increasing concentrations of thrombin both at 8 mg/ml (1.60 +/- 0.024, 1.67 +/- 0.022, 1.74 +/- 0.079) and 12 mg/ml fibrinogen concentrations (1.63 +/- 0.02, 1.87 +/- 0.019, 1.95 +/- 0.014). On the other hand, TGP decreased for both 8 mg/ml (1089 +/- 265, 637 +/- 80, 223 +/- 22 seconds) and 12 mg/ml fibrinogen concentrations (2008 +/- 247, 776 +/- 20, 410 +/- 20 seconds). In contrast to previous studies investigating whole blood, TGP increased with higher fibrinogen levels. CONCLUSIONS: The findings from this fibrin-thrombin clot model confirmed that df and TGP can detect changes in the incipient clot following manipulation of fibrinogen and thrombin concentration. df increases (indicating stronger clot) with higher concentrations of thrombin and fibrinogen. On the other hand, TGP decreased as expected with higher thrombin level but not with higher fibrinogen concentrations.